HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for CG Oncology (NASDAQ:CGON) and maintained a price target of $75, indicating confidence in the company's future performance.
September 17, 2024 | 10:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for CG Oncology and maintained a $75 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $75 price target by HC Wainwright & Co. indicates strong confidence in CG Oncology's future performance. This positive analyst sentiment is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100